Q-omics provides the consensus-scored PABPC1L2B profile across patient tissues and cancer cell-line models. PABPC1L2B expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, PABPC1L2B is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, PABPC1L2B RNA expression shows 10,008 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CHOL, HNSC, and GBM as cancer lineages where PABPC1L2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PABPC1L2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PABPC1L2B survival associations across molecular data types. PABPC1L2B RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PABPC1L2B RNA expression–survival associations across cancer types. High PABPC1L2B expression shows unfavorable associations in CHOL and THCA, but favorable associations in UCS, LUAD, OV and PAAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for PABPC1L2B RNA expression.
This table summarizes PABPC1L2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PABPC1L2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PABPC1L2B shows lower tumor expression in HNSC, COAD and STAD and higher tumor expression in THCA, PRAD and LUSC. The HNSC box plot shows higher PABPC1L2B RNA expression in normal versus tumor tissue (log2 FC = −0.085, t-test p = .008).
This table shows molecular features associated with PABPC1L2B in patient tissues and cancer cell lines. In patient samples, PABPC1L2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PABPC1L2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and CNS.
